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Ovarian cancer has received national attention as a highly virulent disease. Its lack of early
warning symptoms and the failure to develop highly sensitive screening tests have led some
physicians to recommend prophylactic oophorectomies to women with relatives who have had
ovarian cancer. Others have recommended routine screening of otherwise normal women for
CA 125, a circulating tumor marker, and ultrasound examinations. Each ofthese techniques is
associated with substantial false-positive rates that could lead to unnecessary surgery. A review
ofepidemiologic data suggests that familial ovarian cancer kindreds are rare, but women with
first-degree relatives who have had ovarian cancer have a significant risk themselves for
developingovarian cancer. In addition, womenwith agreat numberofovulatory cycles are at an
increased riskfor the disease. Circulating tumormarkers are frequentlyelevated inwomenwith
advanced ovarian cancer, but their value in early detection of ovarian cancer has yet to be
established. Advances in endovaginal ultrasound and color Doppler flow technology have
significantly improved our ability to assess pelvic organs. This article presents the background,
rationale, and structure of the Yale Early Detection Program for ovarian cancer, whose goals
are to identify the best techniques for diagnosing ovarian cancer in an early stage, to determine
the frequency with which such tests should be employed, to assess false-positive results, and to
identify women who might benefit from prophylactic oophorectomies.
INTRODUCTION
Ovarian cancer is the fifth most common cancer in American women but the
fourth leading cause of cancer death [1]. Among women with pelvic reproductive
cancers, more deaths will occur from ovarian cancer than from cervical and uterine
cancercombined. The American CancerSociety estimates that approximately 20,700
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new cases ofovarian cancer will develop in 1991, and 10,500 women will die in 1991
from this disease [1]. The high mortality from ovarian cancer reflects a lack of early
warning symptoms and a lack of an effective screening procedure. Thus, 70 percent
of women with common epithelial ovarian cancers, which represent approximately
90 percent ofall ovarian malignancies, will present with International Federation of
Gynecologists and Obstetricians (F.I.G.O.) stage III or IV disease, as symptoms
routinely develop onlywhen the cancer has spread to the upper abdomen (stage III)
orbeyond (stage IV) [2]. Thefive-yeardisease-free survival forpatientswithstage III
and IV cancer is approximately 20 percent. Dramatic improvements in treatment,
including aggressive cytoreductive surgery and aggressive chemotherapy, have led to
prolonged survival, but the overwhelming majority of patients with stage III or IV
disease ultimately succumb to the cancer [2-6]. Patients with ovarian cancer diag-
nosed as F.I.G.O. stage I (limited to the ovaries) or II (limited to pelvic metastases)
disease have, however, five-year survival ratesof90 and 70percent, respectively [7,8].
Despite much publicity and campaigns to implement screening programs, there is no
evidence at this time that screening the population at large is an effective approach
for the early detection ofovarian cancer.
Although there has not been an increase in the incidence ofovarian cancer, there
has been an explosion of information transmitted to the public about this disease.
The recent deaths of Governor Ella T. Grasso of Connecticut and Gilda Radner
have focused attention on ovarian cancer in American women. Recent attention in
the mass media has focused on the virulence of ovarian cancer, a role for a tumor
marker, CA 125, and ultrasound screeningforits earlydetection. The implications of
false-positive CA 125 assays and other biological marker tests, particularly in
asymptomatic pre-menopausal women who request ovarian cancer screening, has
caused confusion and conflict between patient and physician. The management of
minimal (1-3 cm) ovarian cysts in post-menopausal women identified only by
screening ultrasound examinations has led to unnecessary surgery. Ofmost concern,
however, is a suggestion from the Gilda Radner Familial Ovarian Cancer Registry
that women who have first-degree relatives with ovarian cancer have up to a 50
percent chance of developing the disease, compared to a 1.4 percent chance in
women without such family histories [9]. This registry suggests routine prophylactic
oophorectomy in such women. Data to support this recommendation, however, have
not been provided. Nevertheless, women in Connecticut are already undergoing
prophylactic oophorectomies based onthis recommendation.
The fact thatphysician practice patterns are evolving in the absence ofsupporting
clinical investigations creates anurgent need to establish aprogram to determine the
most effective early detection procedures forovarian cancer, the limitations ofthese
procedures, and which women would benefit from prophylactic oophorectomies to
avoid subsequently developing ovarian cancer. Ifone could identify a population of




Agroup ofwomen at high risk for developing ovarian cancer has nowbegun to be
recognized. Lynch and colleagues have reported on familial ovarian cancer kindreds
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[10,11]. These kindreds are infrequent in occurrence and often have other cancers
associated with them, in particular breast cancer. The observed cases of ovarian
cancer in these kindreds suggested an autosomal dominant pattern ofinheritance. In
a case-control study of 62 women between the ages of 45-74 admitted to seven
hospitals in Connecticut, Hildreth et al. identified women with first-degree relatives
(mother and sisters) experiencing ovarian cancer having an 18.2-fold (95 percent
confidence limits, 4.8-69.0) elevation in risk for developing cancer ofthe ovary [12].
Cramer et al. estimated byempirical logicthat the relative riskforovarian cancer ifa
primary relative had an ovarian cancer was 11.32 (95 percent confidence limits,
8.87,-) [13]. In that study, no controls had aprimary relativewith ovarian cancer [13].
Schildkraut and Thompson have reviewed data from a population-based case-
control study, the Cancer and Steroid Hormone Study, conducted by the Centers for
Disease Control [14]. In this study, 493 women aged 20-54 who had epithelial
ovarian cancer were compared to a group of 2,465 controls. Ovarian cancer in the
first- and second-degree relatives ofcaseswas significantly more common than in the
relatives of controls, with the odds ratios for ovarian cancer in first- and second-
degree relatives being 3.6 (95 percent confidence interval, 1.8, 7.1) and 2.9 (95
percent confidence interval, 1.6, 5.3), respectively, compared to women with no
family history ofovarian cancer. Schildkraut and Thompson thought their data were
more consistentwith an autosomal dominant mode ofinheritance than an autosomal
recessive mode but suggested a polygenic mode ofinheritance might account for the
familial aggregation patterns observed [14].
Important characteristics of familial ovarian cancer are (1) a tendency for earlier
age at onset, with the mean age being 47.7 years as compared to 59 years for the
general population, and (2) a tendency to be overwhelmingly serous cancers (90-97
percent) that are histologically poorly differentiated [15,16].
Numerous studies in the last two decades have also identified the involvement of
the process of ovulation as a risk for ovarian cancer [10-14,17-19]. The greater the
number of ovulatory cycles, the greater the risk for ovarian cancer. Pregnancy is
associated with anovulation. Therefore, the greater the number of pregnancies a
woman has, the fewer ovulatory cycles she experiences and the lower her risk for
developing ovarian cancer. Breast feeding is associated with prolonged postpartum
amenorrhea. Thus, a woman who has breast-fed her children has fewer ovulatory
cycles than one who has not and has a reduced risk for developing ovarian cancer
[20]. Oral contraceptives function bypreventingovulation and serve aprotective role
with regard to developing ovarian cancer [17]. Finally, an early menarche and a late
menopause increase the number of ovulatory cycles that a woman experiences,
whereas a late menarche and an early menopause have the opposite effect and may
be protective regarding ovarian cancer.
Other factors that have been associated with ovarian cancer risk include diets high
in animal fat, ingestion of lactose, type A blood, childhood mumps, and the use of
talc infeminine hygiene [21-23]. Dietaryfactors have been implicated in the etiology
of numerous cancers; however, the data regarding diet and ovarian cancer risk are
limited and often contradictory. A clearer understanding of dietary risk factors is
needed, due to the lack of primary prevention strategies for ovarian cancer. Some
dietary studies suggest that animal fat, but not vegetable fat, is positively associated
with ovarian cancer risk [24,25]; however, others fail to find an association with total
fat or type offat [26]. Dailyconsumption ofmeat, a significant contributor to dietary
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fat intake, has been associated with an increased risk for ovarian cancer in some
studies [21,25-27]. Daily fish consumption has also been reported to increase risk in
some studies [17,28], although others report an inverse association between ovarian
cancer riskand fish intake [29]. Milkconsumption ispositively associatedwith risk in
some studies [30], while others report a negative association with milk consumption
[27,28]. Mettlin and Piver reported that, while total milk drinking was unassociated
with risk, drinking whole-fat milk significantly increased risk, while drinking low-fat
milk significantly reduced risk [31]. Other dietary factors reported to be protective
against ovarian cancer include vegetables and/or beta-carotene [24,26,29], and
cereals, whole grains, orpasta [29,30]. Finally, alcohol hasbeen reported to decrease
risk [32] or to be unassociated with risk ofovarian cancer [29,33].
Circulating TumorMarkers
Recent developments, particularly in monoclonal antibody technology, have re-
sulted in the identification ofcirculating tumor markers that are frequently elevated
in womenwith ovarian cancer. CA 125 has been the most intensively studied marker
[34,35]. It is an antigenic determinant expressed by an approximately 200 kD
glycoprotein that is detected by the monoclonal antibody OC 125. It is very highly
expressed by derivatives of fetal coelomic epithelium, elevated in the sera of
approximately 80 percent of women with ovarian cancer but is also elevated in
approximately 60percent ofpatientswithpancreaticcarcinoma and 20-25 percentof
patients with other solid tumors [35]. Thus, it is not a specific tumor marker for
ovarian cancer. It is also elevated in primary liver disease, particularly in association
with ascites.
CA 125 levels reflect tumor volume and have been used in the evaluation of the
success of cancer treatment. In ovarian cancer patients who appear to be in
remission, serum CA 125 elevations may be the first indication of treatment failure.
CA 125 has also been used in an attempt to distinguish benign pelvic masses from
malignant ones. Elevations ofCA 125 greater than 35 U/mL inwomen over 50years
of age in association with a pelvic mass are consistent with the diagnosis of ovarian
cancer in 80 percent of women studied [36]. Elevation of CA 125 greater than 35
U/mL in women under 50 years of age in association with a pelvic mass is, however,
associated with ovarian cancer in only 15 percent ofwomen [36]. The false-positive
rate in younger women is most often due to benign pelvic disorders such as
endometriosis, uterine leiomyomata, benign ovarian cysts, and pelvic inflammatory
disease. Thus screeningwomen under age 50 exclusivelywith CA 125 will result in a
high frequency of elevated marker values. An effective early detection program for
ovarian cancer must consider incorporating a panel of circulating markers or
alternative techniques such as pelvic ultrasound examinations.
Lipid-associated sialic acid in plasma (LSA) measures sialic acid present in the
lipoprotein/glycoprotein fraction ofplasma [37]. This fraction contains gangliosides
and other cell membrane components. The assay methodology includes organic
extraction of plasma and colorimetric determinations of lipid-bound sialic acid.
Lipid-associated sialic acid in plasma was found to be elevated in a large group of
women with ovarian cancer managed at Yale University School ofMedicine [37]. Its
elevation was similar to that of CA 125 in women with ovarian malignancies.
Lipid-associated sialic acid in plasma is a nonspecific marker, however, and can be
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associated with many malignancies. It is frequently elevated when an inflammatory
process is present. Thus, itmayplay a role in the management of patients known to
have cancer, but its interpretation in patients with pelvic masses is subject to
limitations because of the nonspecific nature of this test.
Urinary gonadotropin fragment (UGF) or urinary gonadotropin peptide (UGP) is
a small protein (molecularweight, 9,700) evincing sequence homologywith segments
ofthe human chorionic gonadotropin (hCG) beta subunit (molecular weight, 36,700)
[38-40]. Like CA 125, it is produced primarily by ovarian cancers and, to a lesser
extent, by endometrial, breast, and pancreatic malignancies [39,40]. Indeed, UGF
tends to be found in the urine ofwomen with ovarian cancer at about the same rate
as CA 125 in studies performed at Yale University [38,39]. UGF may be elevated in
patients whose tumors do not express CA 125 (detects >90 percent of those
false-negative for CA 125) [40]. UGF may be useful in pre-operatively assessing
young women withpelvic masses inwhom CA 125 has already been established to be
elevated. An elevated UGF assay, in association with a substantially elevated CA
125, strongly supports the diagnosis of an ovarian cancer, whereas, if the UGF is
normal in the presence of amildly elevated CA 125, a benign gynecologic process is
more likely [40].
NB/70K is a glycoprotein extracted from human ovarian cancers. It was initially
reported to be elevated in the sera of 60 percent of post-operative ovarian cancer
patients [41,42]. Elevations of NB/70K are associated with advanced-stage disease
and increasing residual tumor volumes. Unlike CA 125, NB/70K is not associated
with any particular ovarian cancer histology or grade of differentiation. It was
elevated in 45 percent (9/20) of stage I, well-differentiated, ovarian cancers [41].
NB/70Kis also elevated in33-41percent ofnon-gynecologic cancers tested and in 21
percent of cervical and endometrial cancers [42]. We are currently incorporating
NB/70K into apanel oftumormarkers, including CA 125 and lipid-associated sialic
acid in plasma, more effectively to establish pre-operatively the nature of pelvic
masses in women.
Other markers that have been employed in the evaluation of adnexal masses
include TAG 72, CA 15-3, CA 19-9, placental alkaline phosphatase (PLAP), and
PLAP-like alkaline phosphatase [43]. TAG 72 is a glycoprotein detected by the
monoclonal antibodyB72.3,using an immunoradiometric assay [44]. The assay is not
specific for ovarian cancer. TAG 72 does not tend to be elevated in the sera of
women with falsely elevated CA 125 levels. It is not as sensitive as CA 125 in
detecting ovarianmalignancies but has beenincorporated into a tumor marker panel
for assessing women with pelvic masses to determine pre-operatively the nature of
the mass [44]. The serum CA 15-3 immunoradiometric assay measures antigenic
determinants on a glycoprotein of high molecular weight which are frequently
associated with breast and ovarian malignancies [44]. These tumor-associated anti-
gens are infrequently elevated in sera containing false-positive levels of CA 125. CA
15-3 has beenincorporated into apanel oftumor markers for assessing the nature of
pelvicmasses [44]. CA 19-9, acarbohydrate determinant, has been assayed in serum
from ovarian cancer patients and has a limited role in evaluating women with this
disease[45,46]. Itmaybemostusefulinfollowingpatientswithmucinouscarcinomas
of the ovary in whom CA 125 is frequently not elevated. PLAP and PLAP-like
alkaline phosphatase are less likely to be elevated in the sera of women with
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epithelial ovarian cancer than CA 125 but may be highly expressed in sera from
women with endometrioid carcinomas ofthe ovary [43,44].
The lack of sensitivity and/or specificity of individual tumor markers for ovarian
cancer has led to incorporating combinations of these markers (UGF and CA 125;
CA 125, LSA, and NB/70K; CA 125, TAG 72, and CA 15-3, and others) in assessing
patients with pelvic masses [40,43,46-48]. Multi-marker panels are likely to be more
sensitive than single markers for distinguishing ovarian cancer from benign pelvic
masses. The converse may, however, also hold true. Ifthe markers are all normal, the
patient may have a benign process. This possibility is extremely important informa-
tion as women, who are at high risk for ovarian cancer and have adnexal masses,
should be operated on by physicians prepared to perform aggressive debulking
surgery and careful intra-abdominal staging procedures. Women with pelvic masses
and a negative panel of circulating tumor markers are at low risk for gynecologic
malignancies.
Ultrasound Screeningfor Ovarian Cancer
To date, the standard ultrasound examination ofthe ovary hasbeen a transabdom-
inal approach [49,50]. Campbell et al. recently reported on 5,479 self-referred
asymptomatic pre- and post-menopausal women who were scheduled to undergo
three annualtransabdominal ultrasound screensevaluatingovariansize andmorphol-
ogy for abnormalities [49]. These women were not selected as being at high risk for
ovarian cancer. Of the group, 326 women had positive results, but only five were
identified as having ovarian cancer (four stage IA, one stage IB; two at screen 1, and
two at screen 2; prevalence 0.09 percent) [49]. The odds that a positive transabdomi-
nal screen indicated the presence of an ovarian mass, a benign tumor, or any cancer
or primary ovarian cancer were about 4 to 1, 2 to 1, 1 to 26, and 1 to 50, respectively.
Recently developed high-resolution endovaginal ultrasound probes have become
available; these devices adequately visualize both normal and abnormal ovaries
[51,52]. These transducers yield much more information because of the proximity
of the ovaries to the vagina, which allows the use of high-frequency resolution.
Transvaginal sonography is easy to perform, as it does not require a full bladder, is
well tolerated by women, and may accurately detect very small ovarian tumors [52].
The largest transvaginal ultrasound screening experience to date has been reported
byvan Nagell et al. [52]. One thousand asymptomatic women over age 40 have been
evaluated, 75 of whom had an unspecified family history of ovarian cancer. Thirty-
one patients in the entire series were found to have an abnormal vaginal sonogram,
one ofwhom had an ovarian cancer.
Combined TumorMarkerand Ultrasound Screening
CA 125 assays have notbeen reportedlyemployed in the early detection ofovarian
cancer in a high-risk population. Recently, CA 125 has been reported to be effective
as part of an ovarian cancer detection program in 1,010 post-menopausal volunteers
[53]. That program included vaginal examinations and transabdominal ultrasound
examinations. One post-menopausal woman in the series was found to have a pelvic
mass associated with an elevated CA 125 (32 U/mL) and an abnormal ultrasound
examination. The massproved tobe a stage IAclear-cell carcinomaofthe ovary. The
specificity for the combination of CA 125 and vaginal examination with or without
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ultrasound examination was 100 percent (95 percent confidence intervals, 99.6-100
percent) with a minimum follow-up of 12 months for all patients.
Prophylactic Oophorectomy in thePrevention ofOvarian Cancer
Prophylactic oophorectomy has been recommended for women in the rare breast-
ovarian cancer family syndrome, where an autosomal dominant pattern of inherit-
ance forovarian cancer hasbeen documented [11]. It mustbe stressed, however, that
kindreds ofbreast and ovarian cancers occurring in families as described byLynch et
al. is averyunusual event [11]. Nevertheless, three of28 suchwomenwhounderwent
prophylactic oophorectomies subsequently developed intra-abdominal carcinomato-
sis indistinguishable from ovarian cancer [45]. Anecdotal experience and personal
observations suggest several reasons for this phenomenon's occurrence. One is an
inadequate microscopic evaluation of the ovaries [54]. A second is incomplete
resection ofall ovarian tissue, as gynecologists do not routinely expose the retroperi-
toneal space and isolate the infundibulopelvic ligamentvessels and ureter, as theytry
toavoiduretericinjury. In addition, mostpatientsundergoingprophylacticoophorec-
tomy have the procedure performed through small Pfannenstiel incisions or vaginal
approaches, which are inadequate for the proper staging ofan ovarian cancer.
THE YALE OVARIAN CANCER DETECTION PROGRAM
An ovarian cancer detection program concentrating on women at high risk for the
disease is needed to identify the most effective procedures for the early detection of
ovarian cancer, how often these tests should be employed, and how they should be
interpreted. Screening recommendations developed for the high-risk group should
be applicable for low-risk women seen in community practice settings. At present,
circulating tumor markers and ultrasound examinations are being employed in a
haphazard manner, at the discretion of clinicians and often at the urging of
individual patients. The effect on health care costs for these services has yet to be
assessed but undoubtedly is substantial. Information is also needed to develop
criteria for recommending which women will benefit from prophylactic oophorec-
tomy. At this time, it appears that prophylacticoophorectomyis appropriate in those
rare kindreds where ovarian cancer is inherited in an autosomal dominant pattern
[11]. The fraction of families with two or more first-degree relatives with epithelial
ovarian cancer is somewhere between 0.7-5.8 percent of all families of ovarian
cancer patients [55]. Evidence hasyet to be provided demonstrating that anywoman
with afirst-degree relative who has had an epithelial ovarian cancer has a 50 percent
risk for developing ovarian cancer.
The purpose of the newly established Yale Ovarian Cancer Early Detection
Program is to establish the value of a screening program for the early detection of
this devastating disease. Women in Connecticut athigh riskforovarian cancer (those
possessing first-degree relatives with a history of ovarian cancer), age 35 years or
older, are invited to join the detection program. The objective is to try multiple
methods to detect malignancy in its earliest stages (stage I and II), when it is still
curable (five-year survival 90 percent and 70 percent, respectively) rather than at
stages III and IV, its usual presenting stages, when survivability is poor (<20
percent). A panel of circulating tumor markers and diagnostic imaging techniques
are studied in a serial fashion. Tests most useful inrecognizing ovarian cancerwillbe




1. Evaluate the following studies to identify women who have early-stage ovarian cancer:
a. A panel ofcontemporary putative tumor markers, including CA 125, LSA, NB/70K
b. Investigational tumor markers, including colony stimulating factor-1 (CSF-1), serum beta-core
fragment-carrier complex (BCF-COMPLEX)
c. Urinary gonadotropin fragment (UGF)
d. Endovaginal ultrasound studies
2. Monitor the value ofserial circulating tumor markers and endovaginal ultrasound studies to establish:
a. How often these fail bygiving false-positive results in the absence ofcancer
b. The clinical strategies to assess the cause ofthese failures
c. How often and which tests are best for the early detection ofovarian cancer
3. Identify individuals at high risk for ovarian cancerwho may benefit from prophylactic oophorectomy
by:
a. Assessing their personal history, including medical, nutritional, and personal hygiene habits
b. Their family history
c. The results ofcirculating tumor markervalues
d. The results ofendovaginal ultrasound studies
e. Cytogenetic studies
will be established. In addition, epidemiologic data will be analyzed to determine
which women might benefit from prophylactic oophorectomy (Table 1).
Participants are accrued through self-referral aswell as through physician referral
recruiting techniques. They become acquainted with our program through the mass
media aswell asviacommunication withphysiciansthroughout the State ofConnect-
icut by means of such mailings as the Yale Comprehensive Cancer Center Caring.
This study will also be highlighted at the 1991 annual Ella T. Grasso Memorial
Conference, a full-day symposium dedicated to new developments in the diagnosis
and treatment ofgynecologic malignancies, which is attended by many Connecticut
gynecologists and medical oncologists.
Each year, the Division of Gynecologic Oncology at Yale University treats or
consults on 50-70 new cases of ovarian cancer and is involved in the care of
approximately 15-20 women, originally diagnosed and treated at other hospitals in
Connecticut, who develop recurrent ovarian cancer. The families ofwomen treated
at Yale University are contacted, informed ofthe program, and invited to participate
in it.
Participants call the registration secretaries for entry into the study and are
screened through the initial telephone call to ascertain that they have at least one
first-degree relative with ovarian cancer. Women eligible for participation are then
sent an extensive medical and family history form to complete prior to being seen in
the outpatient clinicfacility. Once the completed medical andfamilyhistoryform has
been received and reviewed bythe clinical coordinator, the patient is invited to come
to the Yale Gynecologic Oncology Center for further evaluation.
All participants are seen initially by a medical social worker, at which time an
overall profile ofthe participant is obtained and furtherclarification and additions to
the history obtained. The social worker in the Ovarian Cancer Detection Program,
who provides the linkbetween the medical members ofthe team and the participant,
uses the participant's self-reported survey to enhance the psychosocial assessment
and to provide consistent and broader meaningful histories. In our experience,
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participants will frequently share more detailed information with a social worker
who is not perceived as a deliverer of medical services. The social worker also
communicates the details of the study to the. participant in non-medical terms that
are more easily understood.
The nursing staffthen explain the nature ofthe laboratory tests to be obtained and
answer any questions the participants may have regarding the Ovarian Cancer
Detection Program. The participants then have blood drawn for circulating tumor
markers and cytogenetic studies, and samples of white blood cells undergo DNA
extraction for future molecular genetic studies. Plasma obtained at the initial visit is
stored forfuture circulating tumormarker studies, as newmarkersbecome available.
Urine is obtained for tumor markers. The subjects then undergo a physical examina-
tion by one ofthe physicians in the project, and any questions that theymay have are
answered. The physical examination is a routine complete physical examination,
including a pelvic examination. Stool is checked for occult blood. If the participant
has a normal examination and circulating tumor markers are normal (blood and
urine), she is asked to return at three months for an endovaginal ultrasound
examination and endovaginal color Doppler flow studies to evaluate the ovaries and
the uterus. The subject returns at six months for a physical examination, including a
pelvic examination and circulating tumor marker studies. The participant returns at
nine months for a repeat endovaginal ultrasound and color Doppler flow study and,
at the end of one year, for a repeat physical examination and study of circulating
tumor markers (Fig. 1). The total costs for participation in the first year ofthe study
are currently estimated to be $583.00 (Table 2).
Participants are informedbymail ofnormal laboratory results at the completion of
each cycle oftesting. They are called when abnormal laboratory results are evident.
Referring physicians are also informed ofthe findings for theirpatients.
Blood and urine samples for the tumor markers selected for analysis in the Yale
Ovarian Cancer Detection Program, CA 125, LSA, NB/70K, and UGF are obtained
on entryto the studyand at sixmonths and 12months later. Assayswillbeperformed
at Dianon Systems, Inc., a reference laboratory in Stratford, Connecticut. Plasma
and urine are stored at Dianon Systems, Inc., to be utilized if new markers for
ovarian cancer detection become available in the future. Blood andurine samples for
research tumor marker assays are obtained at the same intervals. Blood samples
obtained at the initial visit for the cytogenetic and molecular genetic studies are
processed in the Department ofHuman Genetics at Yale University.
Participants with elevated tumor markers have the tests for the markers repeated
in one month. If the markers are significantly elevated, i.e., CA 125 doubled, LSA
increased >8 mg/dL, or NB/70K doubled, the participants promptly undergo
endovaginal ultrasound evaluations. If the markers are not significantly elevated,
participants continue with the established protocol.
The results of tumor marker testing will allow us to establish which markers are
best for early detection of ovarian cancer. Moreover, it is our goal to determine the
optimal timing for performance ofsuch tests. Departures from stationary levels may
require more frequent testing to evaluate whether a true departure from constancy is
emerging, or whether the value arose simply as a consequence of variability, and
there is a subsequent return to baseline constancy. Participants are more likely to
have false-positive individual tests due to the nonspecific nature of the circulating
tumor markers. By monitoring these tests in serial fashion, a data base will become
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FIG. 1. Ovarian cancer screening program first-year flow diagram. LSA, lipid-associated sialic acid in
plasma; CSF-1, colony stimulating factor 1; UGF, urinary gonadotropin fragment.
available to clinicians, one that will allow us to pursue alternate clinical strategies
rather than promptly performing unnecessary oophorectomies in these women.
The diagnostic imaging technique to be employed primarily for screening in the
Yale program isthe endovaginalultrasound [18,19]. Endovaginal ultrasound (EVUS)
is used to examine the morphology and vascularity of the ovaries; the ovaries are
located and carefully examined for size and morphology. The presence of any
masses, cystic or solid, are noted and measured. The presence ofany free peritoneal
fluid is noted. After studying the morphology, color flow is utilized, and the ovaries
again carefully examined forvascularity. Any arterial vascularity detected is quanti-
tated by pulse Doppler. The Doppler signal is optimized to maximize peak systolic
TABLE 2
Early Detection Costs: First Year
1. Initial Visit
History and physical examination $105.00
Biomarker assays $ 36.00
2. Three Months
Ultrasound examination and clinical interpretation $125.00
3. Six Months
History and physical examination $ 60.00
Biomarker assays $ 36.00
4. Nine Months
Ultrasound examination and clinical interpretation $125.00
5. Twelve Months
History and physical examination $ 60.00
Biomarkerassays $ 36.00
Total Costs $583.00
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flow and signal amplitude. The signal is recorded and subjected to fast Fourier
transform (FFT) to yield a time-velocity spectrum.
Signal analyses are then performed on line toyield the resistive index (RI), which
is a semi-quantitative parameter of impedance. The spectra are also recorded on
Super VHS for further analysis in the flow lab, yielding a LaPlace transform to
characterize the signals better. Persistent low-impedance flow (RI < 0.5) has been
found in our preliminary work and that reported from the group in London and
Zagreb as being typical ofneovascularity [56,57].
The timing of the examination is critical in pre-menopausal women. Taylor et al.
first showed in 1985 that functional flow associated with the corpus luteum could be
detected in the ovulating ovary by the pulse Doppler technique [58]. This low-
impedance physiologic flow is similar to that seen in ovarian cancer, at least as far as
resistive indices are concerned. Thus, it is important to avoid confusionbyexamining
pre-menopausal women in the first eight days of their cycle, before luteal flow is
manifest. Ifpersistent functional flow is observed early in the cycle, repeat examina-
tion one month later usually demonstrates functional flow in the contralateral ovary.
Timing is of less importance in the post-menopausal patient, who should not
demonstrate functional flow. This flow may, however, be found in peri-menopausal
women and also in patients followinghysterectomy, and repeatscanning isimportant
to differentiate between temporary physiologic flow and the pathologic neovascular-
ity associated with ovarian cancer.
As far as morphologic criteria are concerned, a variety of different appearances
are evaluated. Since the ovarian sizevarieswith the patient's age, the size criteriafor
pre-menopausal women have to be more generous than those for post-menopausal
patients. Particular attention is paid to the characteristics of any cyst, especially
where mural thickening is apparent or where suspicion of malignant disease is
heightened by the presence of abnormal vascularity and/or elevated serum CA 125
level. Differentiation between functional cysts and ovarian cancers should be possi-
ble by repeat scanning.
Participants with abnormal endovaginal ultrasound studies will have the findings
reviewed in a multi-disciplinary bimonthly conference and correlated with physical
examinations and circulating tumor marker determinations. Participants with find-
ings compatible with ovarian cancer are recommended to undergo surgery. Those
with equivocal findings by imaging have repeat imaging studies, including magnetic
resonance imaging studies to define their abnormality further.
The results of the endovaginal ultrasound study are at risk for false-positive
findings, particularly in the pre-menopausal women, who are an important group to
follow, as the median age of familial ovarian cancer patients is only 48 years [16].
Repeat ultrasound examinations, other imaging studies, and their correlation with
physical examinations and circulating tumor markers are essential before oophorec-
tomy is recommended in women with endovaginal ultrasound findings compatible
with ovarian cancer.
Each participant in the Yale program is encouraged to follow American Cancer
Society recommendations for mammography and is requested to have mammogram
resultsforwarded to us at the regularly scheduled intervals. Post-menopausal women
are encouraged to have at least one endometrial sampling at the time of entry into
the study or at any time thereafter if post-menopausal bleeding develops or if the
endovaginal ultrasound examination suggests an endometrial abnormality. Partici-
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pants routinely being followed with Pap smears by community physicians are asked
to forward the results to us. Pap smears are performed on women who are not
undergoing routine Pap smear screening. Participants have stool checked for occult
blood at eachvisit at which a pelvic examination is performed.
All data collected are forwarded to the data coordinating center, Yale University
School of Medicine Biostatistics Consulting Unit (YSMBCU), Laboratory ofEpide-
miology and Public Health. The YSMBCU maintains an on-line inventory of all
studypatients and forms received to date. Acomputerprogram isused to summarize
pre-treatment information on patients entered into the study and test results.
Forms are reviewed briefly by data entry personnel for correctness, completeness,
and consistency. Data are then keyed on to diskettes, verified, transmitted, and
stored on-line. Computer-driven edit checks will be developed to identify missing,
out-of-range, and inconsistent values. This program will generate separate error
notices for each patient and identify the form in which the errors were noted. A
separate filewillbe kept to contain the data in question and the typeoferror; thisfile
will be used to edit the necessary data when the requested information is returned.
When the errors are corrected, the corrected data will be merged with the analysis
data base. Acomputerized record will be kept oftypes oferrors in order to ensure a
high level of data integrity. Multiple copies of the main data files will be extracted
periodically from these files for the generation ofreports.
Participants will be followed indefinitely as long as they are willing to continue to
remain in this project. The Connecticut Tumor Registry has agreed to provide
annually the names of all women in Connecticut diagnosed with ovarian cancer.
Thus, women who drop out of the study can still be followed with regard to their
subsequently developing ovarian cancer. Data will also be analyzed to identify
epidemiologic characteristics ofthose women who might best benefit by undergoing
prophylactic oophorectomy.
One of the primary goals of this study is to characterize the usefulness of
commercial and investigational tumor tests for use in ovarian cancer screening
programs. In addition, we wish to determine the frequency with which such tests
should be employed. The overwhelming majority of subjects entering the program
will remain ovarian cancer-free throughout the studyperiod, i.e., roughly 98 percent
will not develop ovarian cancer. This estimate was derived from two independent
sources, the SEER program data tables and Schildkraut and Thompson [14].
Assuming that wewill enter 200subjects peryear, we expect to accrue approximately
1,000 high-riskwomen into ourproposed five-yearstudy. This numberofsubjectswill
guarantee that our study goals can be addressed. First, we will be able to identify,
with a high degree of precision, the proportion of subjects in this well-defined,
high-risk population who will develop ovarian cancer. The 95 percent two-sided
confidence limit about the observed proportionwill be + 1 percent. In addition, with
our extensive collection of baseline data, we will be able effectively to characterize
this high-risk population and to define the time to failure precisely (i.e., detection of
ovarian cancer) for subjects in this group. The number ofsubjects alsowill guarantee
that, for certain subgroups of interest (e.g., how many subjects with moderately
elevated marker tests who do not go on to develop ovarian cancer), the 95 percent
two-sided confidence limits about the observed proportion of subjects who develop
ovarian cancer will be small. Moreover, if we observe that the test results are
constant over time with limited variability, we can reduce their frequency. This
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evaluation will be performed by fitting a regression equation to each subject'svalues
over time and then showing that the slopes of the regression lines hover about a
certain value. With this large number of subjects, we will be able to obtain highly
precise estimates ofthevariability ofthese slopes andtherebyidentifythe stabilityof
testvalues over time.
The major strength ofthe Yale program forthe earlydetectionofovariancanceris
that the patientpopulationwillbe restricted towomen athighriskfordevelopingthe
disease. To our knowledge, this study is a unique program in that all others have
concentrated on either post-menopausal women or broad population-based screen-
ing. It is believed that the data obtained from the women at high risk for ovarian
cancer will be sufficient to make rational screening recommendations for low-risk
women as well. Such recommendations do not exist at present. The faculty involved
in this program are multi-disciplinary with very strong proven expertise in the
diagnosis and management of ovarian cancer. A strong basis for clinical decision
making for physicians should be an early outcome of this study. At present, the
applications ofcirculating tumormarkers and ultrasound examinations for detection
of ovarian cancer are being done in a haphazard fashion by physicians in clinical
practice. This program should be able to give firm guidelines for ovarian cancer
screening procedures and for responding to abnormal tests resulting from such
screening.
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